Shares of OncoGenex Pharmaceuticals (NASDAQ: OGXI) were crushed today, after the company's most advanced drug candidate, Custirsen, flopped in a phase 3 trial.
The drug did not improve median overall survival, the primary endpoint of its late-stage trial in patients with metastatic castration-resistant prostate cancer (or CRPC), in a statistically significant way. When taken in combination with prednisone and docetaxel, Custirsen helped generate median overall survival of 23.4 months, as compared to 22.2 months for patients taking prednisone and docetaxel only.
OncoGenex has Custirsen in late-stage trials for several other indications and another drug candidate, Apatorsen, in mid-stage trials (some of which are due to read out later this year). So, should investors consider the massive drop an opportunity to get shares at a cheaper price? In the video below, Motley Fool health care analysts David Williamson and Michael Douglass answer.
Even if OncoGenex bounces back from today's mauling, it could have serious trouble keeping up with this top stock
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson, Michael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.